Eurofins Announces AOAC and Afnor Certification for BACGene and BACSpec Listeria kits
July 04 2017 - 9:58AM
Business Wire
Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), a global leader in
bioanalytical testing, announces that its real-time PCR kits for
Listeria testing, BACGene Listeria, as well as the BACSpec Listeria
ELISA kit have received certification by AOAC and AFNOR.
Fast and efficient detection of food borne pathogens is the key
factor for food testing laboratories in order to support their
customers with the quality assurance of their products. Food
producers expect their laboratories to work with methods that have
been tested and recognized by international certification bodies.
Eurofins’ BACGene Listeria kits now entirely fulfill these
requirements.
Classical cultural methods for bacteria are time-intensive and
laborious. The use of efficient methods is becoming increasingly
important for microbiological laboratories. Eurofins’ PCR and ELISA
kits for the detection of Listeria offer laboratories fast and
reliable results.
BACGene Listeria Multiplex is the first true multiplex real-time
PCR detection for Listeria spp. and Listeria monocytogenes in one
single reaction, thus providing a better work and cost efficiency
for microbiology laboratories. If just one target is of interest,
the real-time PCR kits BACGene Listeria monocytogenes and BACGene
Listeria spp. are alternatively available. All kits offer the
fastest time-to-result and are certified for food and environmental
samples by AFNOR Certification as an alternative method for
Listeria monocytogenes and Listeria spp. according to EN ISO 16140
and by AOAC-Research Institute under the Performance Tested
MethodsSM Program.
BACSpec Listeria is a fast, robust and cost effective ELISA kit
to detect Listeria in various food and environmental samples. The
kit is certified for food and environmental samples by AFNOR
Certification as an alternative method for Listeria spp. according
to EN ISO 16140 and by AOAC-Research Institute under the
Performance Tested MethodsSM Program.
These kits enable microbiology laboratories to offer their
customers state-of-the-art assays. The methods are specifically
designed, validated and certified based on customer requirements.
The certifications include MALDI-TOF as a confirmation method,
thereby decreasing the overall analysis time.
The Listeria kits enhance Eurofins product portfolio for
pathogen detection which already comprises the BACGene Salmonella
spp. real-time kit (AOAC PTM and AFNOR certified) and the BACSpec
Salmonella kit (AOAC certified). These products are available to
customers who run microbiological laboratories.
For more information, please visit
www.eurofins.com.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 28,000
staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170704005255/en/
Eurofins GeneScan GmbHDr. Nicholas Krohn, Phone: +49 761 5038
100Email: NicholasKrohn@eurofins.comorEurofins ScientificInvestor
RelationsPhone: +32 2 766 1620orFor inquiries about our productsIn
North America:Eurofins Technologies North America:
technologies.us@eurofins.comIn France:Eurofins Technologies France:
technologies.fr@eurofins.comIn Asia Pacific:Eurofins Technologies
Singapore: technologies.apac@eurofins.comIn Italy:Tecna:
technologies.it@eurofins.comIn the Rest of the World:Eurofins
GeneScan: technologies.de@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024